Empagliflozin (EMPA)
Sponsors
Mayo Clinic, National Taiwan University Hospital, University of Sao Paulo, Ain Shams University, Kanokwan Bunsawat
Conditions
Bipolar DepressionBipolar DisorderBlood PressureBrugada Syndrome (BrS)Diabetes MellitusDiabetes Mellitus, Type 2Diabetic NephropathiesEmpgliflozin Cardioprotective Effect
Phase 2
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
RecruitingNCT06729996
Start: 2025-05-29End: 2027-05-31Target: 50Updated: 2026-07-29
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
Not yet recruitingNCT07146880
Start: 2025-09-15End: 2027-09-21Target: 10Updated: 2025-09-12
SGLT2 Adjunct in T1D
CompletedNCT07591077
Start: 2024-11-20End: 2026-02-20Updated: 2026-05-18
the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
RecruitingNCT07692256
Start: 2025-12-01End: 2027-02-01Target: 60Updated: 2026-07-09
Phase 3
Phase 4
Unknown Phase
Empagliflozin Adjunctive Therapy in Bipolar Depression
Not yet recruitingNCT07472920
Start: 2026-03-09End: 2026-12-01Target: 20Updated: 2026-03-16
Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²
CompletedNCT07866235
Start: 2023-10-11End: 2024-04-10Updated: 2026-10-08